Noodles & Company Announces Preliminary Revenue Results for the Fourth Quarter of 2025

Noodles & Company Announces Preliminary Revenue Results for the Fourth Quarter of 2025 Company to Host Investor Meetings at 28th Annual ICR Conference GlobeNewswire January 12, 2026 BROOMFIELD, Colo., Jan. 12, 2026 (GLOBE NEWSWIRE) — Noodles & Company (Nasdaq: NDLS) today released preliminary, unaudited sales results for the fourth fiscal quarter ended December 30, 2025. […]

Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones

Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones GlobeNewswire January 12, 2026 On track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 2026 Received Breakthrough Therapy and Fast Track designations for TARA-002 in LMs; regulatory update expected in 1H 2026 Dosed first patient in THRIVE-3 registrational

Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference

Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 12, 2026 – Approximately $44 million and $125 million in preliminary (unaudited) Revuforj(R) (revumenib) 4Q25 and full year 2025 net revenue, respectively – – Continued acceleration in demand following approval in R/R NPM1m AML, with

MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference

MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference GlobeNewswire January 12, 2026 MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference Interim assessment and enrollment completion for the EscharEx(R) VALUE Phase III trial in venous leg ulcers (VLUs) expected by year-end 2026; expansion to

NewtekOne, Inc. Announces Extension of Exchange Offer for its Notes due 2026

NewtekOne, Inc. Announces Extension of Exchange Offer for its Notes due 2026 GlobeNewswire January 12, 2026 BOCA RATON, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) — NewtekOne, Inc. (“NewtekOne”) today announced that the expiration date with respect to its previously announced offer to exchange (the “Exchange Offer”) its outstanding 5.50% Notes due 2026 (the “Old Notes”)

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025 GlobeNewswire January 12, 2026 ALACHUA, Fla. and TAMPA, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced preliminary unaudited fourth quarter and

KEY Investment Partners Acquires BellRock Brands’ Portfolio, Home of Mary’s Medicinals, Dixie and Other Top Names

KEY Investment Partners Acquires BellRock Brands' Portfolio, Home of Mary's Medicinals, Dixie and Other Top Names Company purchased out of receivership to acquire brand assets and provide working capital for growth; former Curaleaf CEO Joe Bayern to serve as CEO GlobeNewswire January 12, 2026 DENVER, Jan. 12, 2026 (GLOBE NEWSWIRE) — KEY Investment Partners announced

Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy

Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy GlobeNewswire January 12, 2026 LX2020 generally well tolerated across ten participants with no clinically significant complement activation LX2020 transduction, transcription, and increased protein expression observed across participants with dose-dependent response; mean increase in PKP2 protein of 93% in

Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 12, 2026 Full-year 2025 preliminary1 U.S. net product revenues of $689 million SYFOVRE(R) (pegcetacoplan injection) total injection demand grew 17% year-over-year; regulatory submission for prefilled syringe planned in 1H 2026 Strong EMPAVELI(R) (pegcetacoplan) launch in C3G and primary

First Watch Restaurant Group, Inc. Reports Preliminary Operational Metrics for the Fourth Quarter and Fiscal Year 2025

First Watch Restaurant Group, Inc. Reports Preliminary Operational Metrics for the Fourth Quarter and Fiscal Year 2025 GlobeNewswire January 12, 2026 BRADENTON, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) — First Watch Restaurant Group, Inc. (NASDAQ: FWRG) (“First Watch“ or the “Company“), the leading Daytime Dining concept serving breakfast, brunch and lunch, today reported certain preliminary

Scroll to Top